Sequential administration of the native TERT572 cryptic peptide enhances the immune response initiated by its optimized variant TERT572Y in cancer patients

Journal of Immunotherapy

Volumn 34, Issue 9, 2011, Pages 641-650

  Vetsika, Eleni Kyriaki ^a   Papadimitraki, Elisavet ^a   Aggouraki, Despoina ^a   Konsolakis, Georgios ^a   Mela, Marina Eleni ^a   Kotsakis, Athanasios ^b   Christou, Soultana ^b   Patramani, Stefania ^b   Alefantinou, Marina ^b   Kaskara, Ageliki ^c   Christophyllakis, Charalampos ^c   Kosmatopoulos, Kostas ^d   Georgoulias, Vassilis ^a,b,c   Mavroudis, Dimitris ^a,b  

^a UNIVERSITY OF CRETE   (Greece)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^c KAT HOSPITAL   (Greece)

^d INSERM   (France)

Author keywords

cryptic peptide; immunotherapy; telomerase reverse transcriptase; TERT572 specific T cells

Indexed keywords

ENZYME VARIANT; EPITOPE; GAMMA INTERFERON; TELOMERASE REVERSE TRANSCRIPTASE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; KIDNEY CANCER; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MALE; MELANOMA; OVARY CANCER; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE; THYROID CANCER; VACCINATION;

AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CELLS, CULTURED; CLINICAL PROTOCOLS; DRUG RESISTANCE, NEOPLASM; ENZYME-LINKED IMMUNOSPOT ASSAY; EPITOPES, T-LYMPHOCYTE; FEMALE; HLA-A2 ANTIGEN; HUMANS; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MUTATION; NEOPLASMS; PEPTIDE FRAGMENTS; SURVIVAL ANALYSIS; T-LYMPHOCYTES; TELOMERASE; VACCINATION;

EID: 80055003436     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31823284a6     Document Type: Article

References (42)

1. Kim R, Emi M, Tanabe K. Cancer immunoediting from immune surveillance to immune escape. Immunology. 2007;121:1-14. (Pubitemid 46537674)
2. Nagorsen D, Scheibenbogen C, Marincola FM, et al. Natural T cell immunity against cancer. Clin Cancer Res. 2003;9: 4296-4303. (Pubitemid 37248383)
3. Smyth MJ, Dunn GP, Schreiber RD. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol. 2006;90:1-50. (Pubitemid 43765795)
4. van der BP, Zhang Y, Chaux P, et al. Tumor-specific shared antigenic peptides recognized by human T cells. Immunol Rev. 2002;188:51-64. (Pubitemid 35398865)
5. Blasco MA. Telomeres and human disease: ageing, cancer and beyond. Nat Rev Genet. 2005;6:611-622.
6. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science. 1994;266:2011-2015.
7. Hahn WC, Counter CM, Lundberg AS, et al. Creation of human tumour cells with defined genetic elements. Nature. 1999;400:464-468. (Pubitemid 29361801)
8. Hahn WC, Stewart SA, Brooks MW, et al. Inhibition of telomerase limits the growth of human cancer cells. Nat Med. 1999;5:1164-1170. (Pubitemid 29474421)
9. Robbins PF, Kawakami Y. Human tumor antigens recognized by T cells. Curr Opin Immunol. 1996;8:628-636. (Pubitemid 26385390)
10. Van PA, van der BP, Coulie PG, et al. Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunol Rev. 1995;145:229-250.
11. Tourdot S, Scardino A, Saloustrou E, et al. A general strategy to enhance immunogenicity of low-affinity HLA-A2. 1-associated peptides: implication in the identification of cryptic tumor epitopes. Eur J Immunol. 2000;30:3411-3421. (Pubitemid 32005212)
12. Gross DA, Graff-Dubois S, Opolon P, et al. High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy. J Clin Invest. 2004;113:425-433. (Pubitemid 38544186)
13. Scardino A, Gross DA, Alves P, et al. HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy. J Immunol. 2002;168:5900-5906. (Pubitemid 34556179)
14. Hernandez J, Garcia-Pons F, Lone YC, et al. Identification of a human telomerase reverse transcriptase peptide of low affinity for HLA A2.1 that induces cytotoxic T lymphocytes and mediates lysis of tumor cells. Proc Natl Acad Sci USA. 2002;99:12275-12280.
15. Mavroudis D, Bolonakis I, Cornet S, et al. A phase I study of the optimized cryptic peptide TERT(572y) in patients with advanced malignancies. Oncology. 2006;70:306-314. (Pubitemid 44670173)
16. Bolonaki I, Kotsakis A, Papadimitraki E, et al. Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide. J Clin Oncol. 2007;25:2727-2734. (Pubitemid 47123180)
17. Alexander-Miller MA, Leggatt GR, Berzofsky JA. Selective expansion of high-or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc Natl Acad Sci USA. 1996;93:4102-4107. (Pubitemid 26144250)
18. Gallimore A, Dumrese T, Hengartner H, et al. Protective immunity does not correlate with the hierarchy of virus-specific cytotoxic T cell responses to naturally processed peptides. J Exp Med. 1998;187:1647-1657. (Pubitemid 28235106)
19. Zeh HJ III, Perry-Lalley D, Dudley ME, et al. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol. 1999;162:989-994. (Pubitemid 29035425)
20. Meijer SL, Dols A, Jensen SM, et al. Induction of circulating tumor-reactive CD8+ T cells after vaccination of melanoma patients with the gp100 209-2M peptide. J Immunother. 2007;30:533-543. (Pubitemid 46988087)
21. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med. 1998;4:321-327. (Pubitemid 28144091)
22. Parkhurst MR, Salgaller ML, Southwood S, et al. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J Immunol. 1996;157:2539-2548. (Pubitemid 126450467)
23. Valmori D, Fonteneau JF, Lizana CM, et al. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J Immunol. 1998;160:1750-1758. (Pubitemid 28110836)
24. Dudley ME, Nishimura MI, Holt AK, et al. Antitumor immunization with a minimal peptide epitope (G9-209-2M) leads to a functionally heterogeneous CTL response. J Immunother. 1999;22:288-298. (Pubitemid 29309961)
25. Speiser DE, Baumgaertner P, Voelter V, et al. Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen. Proc Natl Acad Sci USA. 2008;105:3849-3854. (Pubitemid 351723488)
26. Clay TM, Custer MC, McKee MD, et al. Changes in the fine specificity of gp100(209-217)-reactive T cells in patients following vaccination with a peptide modified at an HLAA2.1 anchor residue. J Immunol. 1999;162:1749-1755. (Pubitemid 29307054)
27. Gross DA, Graff-Dubois S, Opolon P, et al. High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy. J Clin Invest. 2004;113:425-433. (Pubitemid 38544186)
28. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med. 1998;4:321-327. (Pubitemid 28144091)
29. Babatz J, Rollig C, Lobel B, et al. Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells. Cancer Immunol Immunother. 2006;55:268-276. (Pubitemid 41682575)
30. Robbins PF, Kawakami Y. Human tumor antigens recognized by T cells. Curr Opin Immunol. 1996;8:628-636. (Pubitemid 26385390)
31. Tourdot S, Scardino A, Saloustrou E, et al. A general strategy to enhance immunogenicity of low-affinity HLA-A2. 1-associated peptides: implication in the identification of cryptic tumor epitopes. Eur J Immunol. 2000;30:3411-3421. (Pubitemid 32005212)
32. Alexander-Miller MA. High-avidity CD8+ T cells: optimal soldiers in the war against viruses and tumors. Immunol Res. 2005;31:13-24.
33. Yee C, Savage PA, Lee PP, et al. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J Immunol. 1999;162:2227-2234. (Pubitemid 29288845)
34. Nugent CT, Morgan DJ, Biggs JA, et al. Characterization of CD8+ T lymphocytes that persist after peripheral tolerance to a self antigen expressed in the pancreas. J Immunol. 2000;164: 191-200. (Pubitemid 30012990)
35. Gattinoni L, Powell DJ Jr, Rosenberg SA, et al. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol. 2006;6:383-393.
36. Zeh HJ III, Perry-Lalley D, Dudley ME, et al. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol. 1999;162: 989-994. (Pubitemid 29035425)
37. Bercovici N, Haicheur N, Massicard S, et al. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients. J Immunother (1997). 2008;31: 101-112.
38. de V I, Lesterhuis WJ, Barentsz JO, et al. Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol. 2005;23:1407-1413. (Pubitemid 41679393)
39. Slingluff CL Jr., Petroni GR, Yamshchikov GV, et al. Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule. J Clin Oncol. 2004;22:4474-4485. (Pubitemid 41185113)
40. Zaks TZ, Chappell DB, Rosenberg SA, et al. Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: selective rescue by caspase inhibition. J Immunol. 1999;162:3273-3279. (Pubitemid 29313574)
41. Salazar LG, Coveler AL, Swensen RE, et al. Kinetics of tumorspecific T-cell response development after active immunization in patients with HER-2/neu overexpressing cancers. Clin Immunol. 2007;125:275-280. (Pubitemid 350116715)
42. Speiser DE, Rimoldi D, Batard P, et al. Disease-driven T cell activation predicts immune responses to vaccination against melanoma. Cancer Immun. 2003;3:12.